In patients with relapsing MS, the transition to cladribine from natalizumab is a safe and effective option that provides sustained disease stability.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Children with pediatric-onset multiple sclerosis (POMS) have shorter telomeres, suggesting MS may accelerate biological aging.

Mild cognitive impairment and Alzheimer disease have a low prevalence among newly diagnosed patients with multiple sclerosis.

Cladribine treatment for relapsing multiple sclerosis improves health-related quality of life and preserves cognitive function after 4 years.

Among patients with relapsing multiple sclerosis, 450 mg of ublituximab could be safely infused in 30 minutes at week 24.

Sexual dysfunction and depression are common and associated with increased disability in patients with multiple sclerosis.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).